探讨黛力新联合艾司奥美拉唑对慢性胃炎伴有反流性食管炎的临床治疗效果(1)
DOI：10.16662/j.cnki.1674-0742.2019.35.007
[摘要] 目的 探討黛力新联合艾司奥美拉唑对慢性胃炎伴有反流性食管炎的临床治疗效果。方法 方便选择该院100例2017年1月—2019年2月慢性胃炎伴有反流性食管炎患者。随机分组，A组实施艾司奥美拉唑治疗，B组则实施艾司奥美拉唑+黛力新治疗，比较两组慢性胃炎伴有反流性食管炎疗效;慢性胃炎症状消失时间、反流性食管炎症状消失时间;治疗前后患者慢性胃炎炎性因子指标、反流性食管炎症状积分和生活质量积分;不良反应。结果 B组慢性胃炎伴有反流性食管炎疗效100.00%高于A组72.00%，差异有统计学意义(χ2=8.102，P<0.05) ; B组慢性胃炎症状消失时间、反流性食管炎症状消失时间(16.11±1.46)d、(22.11±1.45)d和A组比较有优势，差异有统计学意义(t=6.913、5.711，P<0.05)。B组2.00%和A组4.00%的不良反应相似，差异无统计学意义(χ2=0.422，P>0.05)。B组慢性胃炎炎性因子指标、反流性食管炎症状积分和生活质量积分相比较A组更好，差异有统计学意义(P<0.05)。结论 艾司奥美拉唑+黛力新治疗慢性胃炎伴有反流性食管炎效果确切，可有效改善患者的病情和缩短诊疗的时间，无明显不良反应，安全性好。
[关键词] 黛力新;艾司奥美拉唑;慢性胃炎伴有反流性食管炎;临床治疗效果
[中图分类号] R573 [文献标识码] A [文章编号] 1674-0742(2019)12(b)-0007-03
To Explore the Clinical Effect of Deanxitwith Omeprazole on Chronic Gastritis with Reflux Esophagitis
WU Li-xian
Department of Internal Medicine， Longyan First Hospital， Longyan， Fujian Province， 364000 China
[Abstract] Objective Convenient elect To investigate the clinical effect of Deanxit combined with Esomeprazole on chronic gastritis with reflux esophagitis. Methods one hundred patients with chronic gastritis with reflux esophagitis were enrolled in the hospital from January 2017 to February 2019. Randomized group， group A was treated with esmeprazole， and group B was treated with esmeprazole + hydrazine. The two groups were compared with chronic gastritis with reflux esophagitis; the time of chronic gastritis disappeared， The disappearance time of reflux esophageal inflammatory symptoms; chronic gastritis inflammatory factor index， reflux esophageal inflammatory syndrome score and quality of life score before and after treatment; adverse reactions. Results Group B chronic gastritis with reflux esophagitis was 100.00% higher than group A 72.00%，the difference was statistically significant (χ2=8.102， P<0.05); group B chronic gastritis disappeared time， reflux esophageal symptoms disappeared (16.11±1.46)d， (22.11±1.45)d and group A have advantages， respectively， the difference was statistically significant(t=6.913，5.711，P<0.05). 2.00% of group B and 4.00% of group A had similar adverse reactions， the difference was not statistically significant(χ2=0.422， P>0.05). Group B chronic gastritis inflammatory factor index， reflux esophageal inflammatory syndrome score and quality of life score were better than group A， the difference was statistically significant(P<0.05). Conclusion Esomeprazole + Deanxit is effective in the treatment of chronic gastritis with reflux esophagitis， which can effectively improve the patient's condition and shorten the time of diagnosis and treatment， without obvious side effects and safety., 百拇医药(吴立先)
[摘要] 目的 探討黛力新联合艾司奥美拉唑对慢性胃炎伴有反流性食管炎的临床治疗效果。方法 方便选择该院100例2017年1月—2019年2月慢性胃炎伴有反流性食管炎患者。随机分组，A组实施艾司奥美拉唑治疗，B组则实施艾司奥美拉唑+黛力新治疗，比较两组慢性胃炎伴有反流性食管炎疗效;慢性胃炎症状消失时间、反流性食管炎症状消失时间;治疗前后患者慢性胃炎炎性因子指标、反流性食管炎症状积分和生活质量积分;不良反应。结果 B组慢性胃炎伴有反流性食管炎疗效100.00%高于A组72.00%，差异有统计学意义(χ2=8.102，P<0.05) ; B组慢性胃炎症状消失时间、反流性食管炎症状消失时间(16.11±1.46)d、(22.11±1.45)d和A组比较有优势，差异有统计学意义(t=6.913、5.711，P<0.05)。B组2.00%和A组4.00%的不良反应相似，差异无统计学意义(χ2=0.422，P>0.05)。B组慢性胃炎炎性因子指标、反流性食管炎症状积分和生活质量积分相比较A组更好，差异有统计学意义(P<0.05)。结论 艾司奥美拉唑+黛力新治疗慢性胃炎伴有反流性食管炎效果确切，可有效改善患者的病情和缩短诊疗的时间，无明显不良反应，安全性好。
[关键词] 黛力新;艾司奥美拉唑;慢性胃炎伴有反流性食管炎;临床治疗效果
[中图分类号] R573 [文献标识码] A [文章编号] 1674-0742(2019)12(b)-0007-03
To Explore the Clinical Effect of Deanxitwith Omeprazole on Chronic Gastritis with Reflux Esophagitis
WU Li-xian
Department of Internal Medicine， Longyan First Hospital， Longyan， Fujian Province， 364000 China
[Abstract] Objective Convenient elect To investigate the clinical effect of Deanxit combined with Esomeprazole on chronic gastritis with reflux esophagitis. Methods one hundred patients with chronic gastritis with reflux esophagitis were enrolled in the hospital from January 2017 to February 2019. Randomized group， group A was treated with esmeprazole， and group B was treated with esmeprazole + hydrazine. The two groups were compared with chronic gastritis with reflux esophagitis; the time of chronic gastritis disappeared， The disappearance time of reflux esophageal inflammatory symptoms; chronic gastritis inflammatory factor index， reflux esophageal inflammatory syndrome score and quality of life score before and after treatment; adverse reactions. Results Group B chronic gastritis with reflux esophagitis was 100.00% higher than group A 72.00%，the difference was statistically significant (χ2=8.102， P<0.05); group B chronic gastritis disappeared time， reflux esophageal symptoms disappeared (16.11±1.46)d， (22.11±1.45)d and group A have advantages， respectively， the difference was statistically significant(t=6.913，5.711，P<0.05). 2.00% of group B and 4.00% of group A had similar adverse reactions， the difference was not statistically significant(χ2=0.422， P>0.05). Group B chronic gastritis inflammatory factor index， reflux esophageal inflammatory syndrome score and quality of life score were better than group A， the difference was statistically significant(P<0.05). Conclusion Esomeprazole + Deanxit is effective in the treatment of chronic gastritis with reflux esophagitis， which can effectively improve the patient's condition and shorten the time of diagnosis and treatment， without obvious side effects and safety., 百拇医药(吴立先)